Month: May 2022

LONDON and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) — Navigator Holdings Ltd. (“Navigator”) (NYSE: NVGS), the owner and operator of the world’s largest fleet of handysize liquefied gas carriers, announced today that it will release its results for the three months ended March 31, 2022 after markets close in New York on Monday, May 23, 2022. The next day, Tuesday, May 24, 2022 at 11:00 A.M. E.D.T., the Company’s management team will host a Zoom conference call and slide presentation to discuss the financial results. Zoom Conference Call DetailsParticipants should register for the conference call and slide presentation through the following link:https://us06web.zoom.us/webinar/register/WN_Uw3rM5rWTjuADbUifAa4DA Or join by phone:United States: +1 929 205 6099United Kingdom: +44 330 088 5830 For a full list of US and International numbers...

Intervest realises within its office portfolio in Mechelen, rental agreement extensions with Galapagos and Borealis. The various Intervest sites in Mechelen Noord, strategically located between Antwerp and Brussels, will be renovated in phases over the coming years to create a sustainable cluster of offices.AttachmentPR_Update Rentals Mechelen_EN

The total number of innovative NME cell/gene therapy and non-NME NDAs has risen since 2020 LONDON, May 19, 2022 (GLOBE NEWSWIRE) — In 2021, the FDA approved 122 New Drug Applications (NDAs) and Biologics License Applications (BLAs), including new molecular entities (NMEs), biologics approved as BLAs through the Center for Biologics Evaluation and Research (CBER), and new formulations of older drugs. There were four NME cell/gene therapy approvals in 2021, the highest over the last decade. These include two cell therapies and two gene-modified cell therapies. The New Drug Approvals and Their Contract Manufacture – 2022 Edition report offered by GlobalData Plc analyzes the performance of the pharmaceutical CMO industry, using NDA and BLA approvals by the FDA and new active substance (NAS) approvals by the European Medicines Agency’s...

The neuroimmunology drug development space is dynamic and of high value LONDON, May 19, 2022 (GLOBE NEWSWIRE) — Neuroimmune communication is complex, bidirectional, and mediated across both neural and humoral pathways. A neuroimmunology drug is an agent that aims to regulate immune system activity to treat neurological diseases with underlying immune pathologies. Of the innovator products marketed for the eight key indications covered in this report, the majority are indicated for multiple sclerosis (MS), followed by neuromyelitis optica spectrum disorder (NMOSD), Alzheimer’s disease (AD), and for myasthenia gravis (MG). Most marketed neuroimmunology products are small molecules, followed by mAbs and recombinant proteins. The list of pipeline neuroimmunology therapeutics currently in development is extensive and holds numerous...

Company announcementfor ROCKWOOL A/SRelease no. 6 – 2022to Nasdaq Copenhagen 19 May 2022 Report on transactions of executives and related parties in ROCKWOOL A/S shares ROCKWOOL A/S has received and hereby provides notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in ROCKWOOL A/S made by persons discharging managerial responsibilities and/or persons closely related with them. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name: Thomas Kähler 2 Reason for the notification a) Position/status: Chairman of the Board of Directors b) Initial notification/Amendment: Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name: ROCKWOOL A/S b) LEI: 213800QRC7LNX935OZ09 4 Details...

The global cybersecurity market size was $125.5 billion in 2020 LONDON, May 19, 2022 (GLOBE NEWSWIRE) — The cybersecurity market is expected to grow at a CAGR of more than 9% during the forecast period. In 2021, enterprises invested more in cybersecurity and cloud architecture due to employees working remotely during the pandemic. This also sparked an M&A boom in the tech sector. Most cybersecurity M&A deals in 2021 were related to managed security services, network security, endpoint security, identity management, and cloud security. Microsoft, which bought cloud infrastructure company CloudKnox, threat intelligence and attack service management firm RiskIQ, and Internet of Things (IoT) security company ReFirm Labs, was one of the leading acquirers in 2021. Google added to its security capabilities by buying Mandiant...

Bank Norwegian ASA has today issued NOK 226* million as a tap issue in ISIN NO0011142572, increasing the total amount of the bond issue to NOK 1 776 million. Settlement date is 23 May 2021.* Corrected volume due to minimum MNOK 2 nominal amount (face value)Contact persons: CEO and CFO, Klara-Lise Aasen; phone +47 47 63 55 83; kaa@banknorwegian.no Head of treasury Mats Benserud; phone +47 95 89 15 39; mbe@banknorwegian.noThis information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Anoto Group AB (“Anoto” or the “Company”) today publishes the ESEF version of its annual report 2021 on the Company’s website, www.anoto.com. It is now available electronically at https://www.anoto.com/investors/reports/. The format of the report is xHTML (Extensible Hypertext Markup Language). In accordance with the requirements for ESEF, the primary financial statements have been provided with XBRL tags. As the ESEF version of the annual report for 2021 is published, the Company’s auditor has issued an updated auditor’s report. Apart from this, there are no differences compared with the annual report for 2021, which was published on April 30, 2022. For further information, please contact: Joonhee Won, CEO, Anoto Group AB For more information about Anoto, please visit www.anoto.com or email ir@anoto.com Anoto Group AB (publ),...

Commonwealth Alternative Care & Jupiter Research Combine Offerings to Bring Infinity Vaporizer to Dispensary Shelves PHOENIX, May 19, 2022 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT” or the “Company”) (NEO:TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development, and retail, today announced that InfinityTM, Jupiter Research LLC’s (“Jupiter”) proprietary all-in-one vaporizer, featuring Commonwealth Alternative Care Inc. (“CAC”) cold press and cured resin cannabis oils will hit shelves tomorrow, Friday, May 20 at both CAC locations, and will soon be available at medical and recreational dispensaries throughout Massachusetts. “Infinity’s launch in Massachusetts provides the best of TILT Holdings: Jupiter’s exemplary...

Bank Norwegian ASA has today issued NOK 225 million as a tap issue in ISIN NO0011142572, increasing the total amount of the bond issue to NOK 1 775 million. Settlement date is 23 May 2021.   Contact persons: CEO and CFO, Klara-Lise Aasen; phone +47 47 63 55 83; kaa@banknorwegian.no Head of treasury Mats Benserud; phone +47 95 89 15 39; mbe@banknorwegian.noThis information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act